Sugary Drinks Tied to 2M Diabetes Cases; Diagnosing LADA; Top GLP-1 for Weight Loss

A total of 2.2 million new type 2 diabetes (T2D) cases and 1.2 million new cardiovascular disease cases worldwide in 2020 were attributable to sugar-sweetened beverages. (Nature Medicine)

Former Endocrine Society President Teresa K. Woodruff, PhD, was one of the recipients of the National Medal of Science for her pioneering work in oncofertility. (Endocrine News)

In a trial of seniors with type 1 diabetes, automated insulin delivery decreased hypoglycemia compared with sensor-augmented pump delivery. (NEJM Evidence)

Mehmet Oz, MD, and Robert F. Kennedy Jr. — tapped by President-elect Donald Trump for high-profile health roles — have clashing views on Medicare coverage of pricey weight-loss drugs. (The Hill)

Looking to differentiate latent autoimmune diabetes in adults (LADA) from early-onset type 1 diabetes? Try checking serum levels of autoantibodies against interferon-alpha isoforms. (Journal of Clinical Endocrinology & Metabolism)

Investigational once-weekly retatrutide yielded the greatest weight loss of all GLP-1 receptor agonists, up to 22.1% after 48 weeks in adults with overweight or obesity and without diabetes, according to a review of 26 randomized trials. (Annals of Internal Medicine)

Eli Lilly asked to join in opposing a lawsuit filed by compounding pharmacies against the FDA over the agency’s decision that Lilly’s weight-loss and diabetes drugs are no longer in short supply. (Reuters via CNBC)

Older Chinese adults with type 2 diabetes reaped a few additional benefits if their spouse engaged in an educational intervention with them. (JAMA Network Open)

Patients on GLP-1 agonists may require a team approach to receive the best care. (STAT)

Acelyrin said its investigational drug lonigutamab for thyroid eye disease is moving ahead to a phase III trial.

Please enable JavaScript to view the comments powered by Disqus.